Virginie Lacronique-Penard

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.

Journal: Nature medicine

Published: October 07, 2022

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Journal: Leukemia & lymphoma

Published: October 12, 2020

Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.

Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.

Journal: Drugs of today (Barcelona, Spain : 1998)

Published: February 15, 2020

Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis.

Journal: Nature

Published: May 24, 2018

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations.

Journal: Leukemia

Published: November 30, 2017

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Journal: Nature medicine

Published: November 05, 2017

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Journal: ACS medicinal chemistry letters

Published: October 13, 2017

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.

Journal: Blood

Published: April 13, 2017

Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.

Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells.

Journal: Haematologica

Published: October 05, 2016

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Journal: Cancer discovery

Published: September 15, 2016

Familial hematological malignancies: new IDH2 mutation.

Familial hematological malignancies: new IDH2 mutation.

Journal: Annals of hematology

Published: August 21, 2016

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model.

Journal: Journal of inherited metabolic disease

Published: March 10, 2016

Showing 1-12 of 19

Last Updated: 09/26/2026